SpringWorks Therapeutics’ (SWTX) “Outperform” Rating Reiterated at Wedbush

Wedbush reaffirmed their outperform rating on shares of SpringWorks Therapeutics (NASDAQ:SWTX) in a research report sent to investors on Wednesday morning, RTT News reports. Wedbush currently has a $77.00 price target on the stock, up from their prior price target of $75.00. Wedbush also issued estimates for SpringWorks Therapeutics’ Q2 2025 earnings at ($0.56) EPS, Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.92) EPS, FY2026 earnings at $0.49 EPS and FY2027 earnings at $3.56 EPS.

Separately, HC Wainwright restated a buy rating and set a $76.00 price objective on shares of SpringWorks Therapeutics in a research report on Wednesday. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of Buy and a consensus price target of $69.50.

SpringWorks Therapeutics Stock Performance

SWTX opened at $41.71 on Wednesday. The firm has a market cap of $3.09 billion, a P/E ratio of -8.11 and a beta of 0.78. The business’s fifty day moving average is $37.72 and its 200-day moving average is $42.60. SpringWorks Therapeutics has a 52-week low of $18.00 and a 52-week high of $53.92.

SpringWorks Therapeutics (NASDAQ:SWTX) last released its earnings results on Wednesday, August 7th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.58. The firm had revenue of $59.73 million during the quarter, compared to the consensus estimate of $34.42 million. SpringWorks Therapeutics’s quarterly revenue was up 59732900.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.25) earnings per share. On average, research analysts predict that SpringWorks Therapeutics will post -3.34 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. First Horizon Advisors Inc. grew its position in SpringWorks Therapeutics by 47.9% during the 2nd quarter. First Horizon Advisors Inc. now owns 1,183 shares of the company’s stock worth $45,000 after acquiring an additional 383 shares during the last quarter. Headlands Technologies LLC bought a new stake in shares of SpringWorks Therapeutics during the fourth quarter worth about $74,000. Strs Ohio bought a new stake in shares of SpringWorks Therapeutics during the fourth quarter worth about $102,000. Allspring Global Investments Holdings LLC acquired a new position in shares of SpringWorks Therapeutics in the second quarter valued at approximately $123,000. Finally, Quarry LP raised its holdings in SpringWorks Therapeutics by 56.3% in the 2nd quarter. Quarry LP now owns 5,000 shares of the company’s stock valued at $188,000 after buying an additional 1,800 shares during the last quarter.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.